Neema Navai, MD, MHCM
Department of Urology, Division of Surgery
About Dr. Neema Navai
I am Professor and Chair of the Department of Urology at The University of Texas MD Anderson Cancer Center, where I lead with a focus on servant leadership and team empowerment. I oversee a dynamic and innovative program dedicated to excellence in patient care, research discovery, and education.
Our department advances hyper-specialized, patient-centered care delivered by a world-class team of experts and dedicated professionals. We are accelerating progress in urologic oncology through transformative research and are deeply committed to shaping the next generation of leaders through best-in-class fellowship training, mentorship, and academic excellence.
In my enterprise role as Special Advisor to the Chief Medical Executives (CME) for Care Development, I drive strategic and operational transformation across MD Anderson. In dyad partnership with the VP of Innovation, I lead efforts to implement digital health platforms and care redesign initiatives that align with clinical leadership and organizational strategy. My focus is on building high-functioning, cross-disciplinary teams that connect operational, clinical, and innovation leaders to expand our impact and meet the needs of more patients.
I have also served on multiple institutional governance committees in patient care informatics and previously led Ambulatory Operations as Medical Director of the Genitourinary Center. My leadership emphasizes high reliability, patient safety, and systems-level excellence, always in service of MD Anderson’s mission to end cancer.
As a clinician and academic, I maintain an active practice focused on bladder cancer, with expertise in robotic surgery and complex urinary reconstruction. I am deeply committed to patient-centered care—guiding patients with empathy, honoring their values, and striving to minimize the quality-of-life impact of major surgical interventions while maintaining outstanding oncologic outcomes.
Present Title & Affiliation
Primary Appointment
Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Chair, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Professor, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Deputy Chair, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2025 | Harvard University, Boston, Massachusetts, US, Masters in Healthcare Management (MHCM) |
| 2004 | Northwestern University Feinberg School of Medicine, Chicago, Illinois, US, MD |
| 2000 | University of Michigan, Ann Arbor, Michigan, US, BS in Cellular and Molecular Biology |
Postgraduate Training
| 2010-2013 | Clinical Specialist, Fellowship, Urologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2009-2010 | Chief Urology Resident, Urology, Northwestern University, Chicago, Illinois |
| 2006-2009 | Urology Resident, Urology, Northwestern University, Chicago, Illinois |
| 2005-2006 | Clinical Residency, General Surgery, Northwestern University, Chicago, Illinois |
| 2004-2005 | Clinical Internship, General Surgery, Northwestern University, Chicago, Illinois |
Licenses & Certifications
| 2022 | Washington Medical Commission |
| 2022 | Louisiana State Board of Medical Examiners |
| 2022 | Tennessee Board of Medical Examiners |
| 2022 | Georgia Composite Medical Board |
| 2022 | Oklahoma Board of Medical Licensure and Supervision |
| 2022 | Alabama Medical Licensure Commission |
| 2022 | Arizona Medical Board |
| 2022 | Mississippi State Board of Medical Licensure |
| 2021 | Florida Telehealth Verification |
| 2015 | American Board of Urology |
| 2010 | Texas Medical Board |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2019
Administrative Appointments/Responsibilities
Chair, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2025 - Present
Special Advisor to Chief Medical Executive, Strategy & Functional Integration (Office of the Chief Medical Executive), The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present
Strategic Decision Owner and Co-Chair Digital Health and Virtual Care, Department of Office of the CME, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present
Deputy Chair, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present
Clinical Medical Director, Department of Genitourinary Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2023
Residency Program Director, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2019
Director of Medical Student Education, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2019
Director Bladder Cancer Robotics, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - Present
Other Professional Positions
Member - 49 States Working Group, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
Team Lead, Concierge Services and Virtual Options - EC Transformation, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
OneConnect: Superuser, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - Present
EPIC Subject matter expert: GU Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - Present
Intramural Institutional Committee Activities
Project leader - upstream, Capacity Management (enterprise), The University of Texas MD Anderson Cancer Center, 2023 - Present
Co-Chair, Ambulatory Operations Informatics, The University of Texas MD Anderson Cancer Center, 2022 - Present
Extramural Institutional Committee Activities
Member, Executive Billing and Compliance Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, AMA E/M Change Sub Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present
Chair, Virtual Care and Engagement, The University of Texas MD Anderson Cancer Center, 2020 - Present
Chair, Preoperative Informatics, The University of Texas MD Anderson Cancer Center, 2019 - Present
Alternate, Division of Surgery Quality Officer, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, Medical Records Committee, The University of Texas MD Anderson Cancer Center, 2018 - Present
Member, EHR Officer, The University of Texas MD Anderson Cancer Center, 2018 - Present
Alternate, OR committee, The University of Texas MD Anderson Cancer Center, 2018 - Present
Member, Division of Surgery Block Working Group, The University of Texas MD Anderson Cancer Center, 2017 - 2023
member, Graduate Medical Education Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2019
Member, Ambulatory Informatics Committee, The University of Texas MD Anderson Cancer Center, 2016 - Present
Member, Clinical Effectiveness Subcommittee, The University of Texas MD Anderson Cancer Center, 2016 - 2019
Member, Division of Surgery EPIC Committee, The University of Texas MD Anderson Cancer Center, 2016 - Present
Member, Data Services Steering Team, The University of Texas MD Anderson Cancer Center, 2016 - Present
Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2015 - 2021
Member, Faculty Academic Review Committee, The University of Texas MD Anderson Cancer Center, 2015 - 2018
Editorial Activities
Editorial Review Board, Annals of Surgical Oncology, 2016 - Present
Honors & Awards
| 2024 - Present | Top 10% Provider Nationally for Delivery of Care, CGCAHPS |
| 2014 | MD Anderson Research-Related Patient Care Clinical Charges Funding, The University of Texas MD Anderson Cancer Center |
| 2013 - 2014 | NIH Bladder Cancer SPORE Career Development Award, The University of Texas MD Anderson Cancer Center |
| 2012 | Best Poster: Bladder Cancer Basic Research III, AUA |
| 2012 | Trainee Excellence Award, The University of Texas MD Anderson Cancer Center |
| 2010 | Leander W. Riba Award, Northwestern University |
| 2010 | SUO December Meeting Fellow/Resident Poster Award, SUO |
| 2009 | Bipin Bhayani Resident Research Awards, Northwestern University |
| 2009 | Huggins Essay Contest, Chicago Urological Society |
| 2008 | Bipin Bhayani Resident Research Awards, Northwestern University |
| 2007 - 2008 | Gerald P. Murphy Memorial Luncheon Scholar, AUA |
| 2007 | Bipin Bhayani Resident Research Awards, Northwestern University |
| 2007 | Society of Urologic Prosthetic Surgeons/Sexual Medicine Society of North America, SUPS/SMSNA |
| 2006 | Huggins Essay Contest, Chicago Urological Society |
| 2003 | Alpha Omega Alpha Honor Society, Northwestern Medical School |
| 2000 | Class Honors, University of Michigan |
Professional Memberships
Selected Presentations & Talks
Regional Presentations
- 2025. Pfizer Inc. Invited. 21st Oncology Updates Advances and Controversies. Steamboat Springs, CO, US.
- 2024. Management of node positive Disease. Panelist. SUO Bladder Cancer Course. Dallas, TX, US.
- 2024. Introduction of the Von Eschenbach Lecturer. Invited. UT 2nd Annual Christopher G. Wood Advances in Urologic Oncology Symposium. Austin, TX, US.
- 2023. Session II (Bladder Ca Localized). Conference. UT Christopher G. Wood Advances In Urologic Oncology Symposium. Austin, TX, US.
National Presentations
- 2025. Bladder Procedures. Panelist. American Urological Association. Las Vegas, Nevada, US.
- . Conference. Aspen Urological Conference. Apsen, CO, US.
- 2024. Surgical Management of Clinically Node Positive Bladder Cancer. Panelist. Bladder Cancer Course. Dallas, Texas, US.
- 2024. Emerging treatments in non muscle invasive bladder cancer. Conference. Aspen Urological Conference. Asoen, CO, US.
- 2023. Surgical management of node positive bladder cancer. Invited. URMC Urology 5th Annual Bladder Cancer Symposium. Rochester, NY, US.
- 2023. ”Robotic Radical Cystectomy and intracorporeal urinary diversions in Female patients- step by step”. Invited. Sao Paulo, BR.
- 2023. Optimal management of cN+ bladder cancer. Conference. Optimal management of cN+ bladder cancer. Chicago, IL, US.
- 2023. Three papers that influenced my practice. Conference. Three papers that influenced my practice. Chicago, IL, US.
- 2023. Bladder Cancer Cases. Conference. The University of Chicago. Aspen, CO, US.
- 2023. Telehealth in the Post Covid Era. Conference. The University of Chicago. Aspen, CO, US.
- 2023. Robotic Radical Cystectomy - Controversy and Evidence. Conference. The University of Chicago. Aspen, CO, US.
- 2023. Clinical Pearls - Node Positive Bladder Cancer. Conference. The University of Chicago. Aspen, CO, US.
- 2022. Telemedicine Presence at MDACC. Conference. UT MD Anderson Cancer Center. Steamboat Springs, CO, US.
- 2021. Speaker: Clinical N+ Disease: What is the Role of Surgical or Radiotherapy Consolidation vs. Check Maintenance Immunotherapy?. Conference. SUO Bladder Cancer Course. Orlando, FL, US.
- 2020. Surgical Management of cM1a Bladder Cancer. Conference. 21st Annual Meeting of Society of Urologic Oncology. Virtual, US.
- 2019. MRI for Staging for Bladder Cancer &ViRads System. Conference. MRI for Staging for Bladder Cancer &ViRads System. Washington, District Of Columbia, US.
- 2019. Individualized Management of Patients with GU Malignancies: A 2019 Update-Management of Patients with Non-Muscle Invasive Bladder Cancer: 2019 and Beyond. Conference. Individualized Management of Patients with GU Malignancies: A 2019 Update. Houston, TX, US.
- 2018. Contemporary Outcomes Of Non-Muscle Invasive Bladder Cancer Patients Treated With BCG. Conference. Contemporary Outcomes Of Non-Muscle Invasive Bladder Cancer Patients Treated With BCG. Phoenix, AZ, US.
- 2018. Comparative analysis of biopsy proven lymph node positive bladder cancer to those with biopsy proven node negative disease prior treatment. Conference. Comparative analysis of biopsy proven lymph node positive bladder cancer to those with biopsy proven node negative disease prior treatment. Phoenix, AZ, US.
- 2018. Drivers of Cost for an Episode of Care in Radical Cystectomy. Conference. Drivers of Cost for an Episode of Care in Radical Cystectomy. San Francisco, CA, US.
- 2018. The Role of Metastatic Burden in Cytoreductive/Consolidative Radical Cystectomy. Conference. The Role of Metastatic Burden in Cytoreductive/Consolidative Radical Cystectomy. San Francisco, CA, US.
- 2017. What is the Best Treatment Option for Patients With Disease After Receiving BCG?: Radical Cystectomy. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2017. Surgical consolidation in the setting of metastatic bladder cancer. Conference. Surgical consolidation in the setting of metastatic bladder cancer. Charlotte, NC, US.
- 2017. Bladder Cancer: Basic Research & Pathophysiology V. Conference. Bladder Cancer: Basic Research & Pathophysiology V. Boston, MA, US.
- 2017. What is the Best Management of cT2 Muscle Invasive Bladder Cancer? - Radical Cystectomy With PLND. Conference. The University of Texas MD Anderson Cancer Center. Steamboat Springs, CO, US.
- 2016. State of the Art: Caring for Radical Cystectomy Patient - Robertic Cystectomy with Intracorporeal Diversion. Conference. The University of Texas MD Anderson Cance Center. Houston, TX, US.
- 2016. Robotic Surgery in Urology. Conference. Robotic Surgery in Urology. Orlando, FL, US.
- 2016. Special Presentation: SPORE Career Development Awardee. Conference. American Urological Association. San Diego, CA, US.
- 2016. Debate: Pro Neoadjuvant Chemotherapy for cT2 Bladder Cancer. Conference. The University of Texas MD Anderson Cancer Center. Steamboat Springs, CO, US.
- 2016. Immunotherapy for Bladder Cancer. Conference. The University of Texas MD Anderson Cancer Center. Steamboat Springs, CO, US.
- 2015. What Is The Best Way To Perform A Radical Cystectomy; Debate: Pro Robotic Surgery for Radical Cystectomy. Conference. What Is The Best Way To Perform A Radical Cystectomy; Debate: Pro Robotic Surgery for Radical Cystectomy. Steamboat Springs, CO, US.
- 2014. Bladder Cancer Overview. Conference. Bladder Cancer Overview. Houston, TX, US.
- 2014. Bladder Cancer Overview. Conference. Bladder Cancer Overview. Dallas, TX, US.
- 2014. Techniques in Robotic Cystectomy and Intracorporeal Urinary Diversion. Conference. Techniques in Robotic Cystectomy and Intracorporeal Urinary Diversion. Houston, TX, US.
- 2014. Who Needs Treatment for Localized Prostate Cancer?. Conference. Who Needs Treatment for Localized Prostate Cancer?. Steamboat Springs, CO, US.
- 2014. Robotic Radical Cystectomy. Conference. Robotic Radical Cystectomy. Steamboat Springs, CO, US.
- 2014. Robotic Cystectomy and Diversion: Tips, Tricks; Partial Cystectomy for Muscle Invasive Bladder Cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2013. Immediate Surgery is Best for High Grade Distal Urethral Tumor. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2012. Decreasing Utiliation of RPLND for clinical stage I non-seminomatous germ cell tumors. Conference. Decreasing Utiliation of RPLND for clinical stage I non-seminomatous germ cell tumors, US.
- 2012. High microRNA expression is associated with increased risk of death frm disease in muscle-invasive urothelial carcinoma of the bladder. Conference. High microRNA expression is associated with increased risk of death frm disease in muscle-invasive urothelial carcinoma of the bladder, US.
- 2012. microRNA200c expression predicts overall survival after radical cystectomy. Conference. microRNA200c expression predicts overall survival after radical cystectomy, US.
- 2011. High microRNA expression is associated with increased risk of death from disease in muscle-invasive urothelial carcinoma of the bladder. Conference. High microRNA expression is associated with increased risk of death from disease in muscle-invasive urothelial carcinoma of the bladder, US.
- 2010. Creation and characterization of a therapeutic nanoparticle platform for the treatment of bladder cancer. Preliminary in-vitro results. Conference. Creation and characterization of a therapeutic nanoparticle platform for the treatment of bladder cancer. Preliminary in-vitro results, US.
- 2010. Genetic variants in the vitamin D pathway genes predict recurrence risk for non-muscle invasive bladder cancer. Conference. Genetic variants in the vitamin D pathway genes predict recurrence risk for non-muscle invasive bladder cancer, US.
- 2008. Demonstrating vesicoureteral reflux by positioning the instillation of contrast (PIC) cystography is a physiological test by manometry. Conference. Demonstrating vesicoureteral reflux by positioning the instillation of contrast (PIC) cystography is a physiological test by manometry, US.
- 2007. Management of renal tumors smaller than 7cm. Conference. Management of renal tumors smaller than 7cm, US.
- 2007. Comparison of surgical outcomes between pure and hand-assisted laparoscopic radical nephrectomy. Conference. Comparison of surgical outcomes between pure and hand-assisted laparoscopic radical nephrectomy, US.
- 2007. Complications of open radical retropubic prostatectomy in potential candidates for active monitoring. Conference. Complications of open radical retropubic prostatectomy in potential candidates for active monitoring, US.
- 2007. Proenzyme forms of prostate specific antigen (pro-psa) are associated with progression-free survival rate after radical prostatectomy. Conference. Proenzyme forms of prostate specific antigen (pro-psa) are associated with progression-free survival rate after radical prostatectomy, US.
- 2007. Neurologin 4 isoform y: a novel marker for prostate cancer. Conference. Neurologin 4 isoform y: a novel marker for prostate cancer, US.
- 2007. Correlation between digital rectal examination findings and pathological findings in the radical prostatectomy specimen. Conference. Correlation between digital rectal examination findings and pathological findings in the radical prostatectomy specimen, US.
- 2006. Single institution experience of complications related to urethral reconstructive surgery: Multivariate analysis of independent risk factors. Conference. Single institution experience of complications related to urethral reconstructive surgery: Multivariate analysis of independent risk factors, US.
International Presentations
- 2025. Thematic Session 'Rapid-fire debates: Common problems and controversies in bladder cancer. Panelist. European Association of Urology 2025. Barcelona, ES.
- 2023. Surgical management of node positive bladder cancer. Invited. TUA and MD Anderson International Uro-Oncological Conference. Taichung, TW.
- 2023. Robotic radical cystectomy - controversies and evidence. Visiting. Taiwan Urologic Association. Taipei, TW.
- 2020. Pathologic outcomes after neoadjuvant chemotherapy for high-risk muscle invasive bladder cancer. Conference. Pathologic outcomes after neoadjuvant chemotherapy for high-risk muscle invasive bladder cancer. Barcelona, ES.
- 2017. Crrent prospectives on robotic cystectomy and hurdles to achieve standard of care. Conference. Crrent prospectives on robotic cystectomy and hurdles to achieve standard of care. Abu Dhabi, AE.
- 2017. What Should You Do When BCG Fails in High Risk Localized Bladder Cancer? Options For Patient Salvage. Conference. What Should You Do When BCG Fails in High Risk Localized Bladder Cancer? Options For Patient Salvage. Taipei, TW.
- 2017. Neoadjvuant Chemotherapy For Locally Advanced Bladder Cancer: Who Needs It, Who Doesn’t, and Why?. Conference. Neoadjvuant Chemotherapy For Locally Advanced Bladder Cancer: Who Needs It, Who Doesn’t, and Why?. Taipei, TW.
- 2017. Tips and Tricks for Robotic Surgery of Genitourinary Malignancies: Radical Cystectomy with Ileal Conduit. Conference. Tips and Tricks for Robotic Surgery of Genitourinary Malignancies: Radical Cystectomy with Ileal Conduit. Taipei, TW.
- 2017. Cost‐Effectiveness of Robot‐Assisted Radical Cystectomy Using a Propensity Matched Cohort. Conference. Cost‐Effectiveness of Robot‐Assisted Radical Cystectomy Using a Propensity Matched Cohort. Lisbon, PT.
- 2016. Treatment of oligometastatic bladder cancer. Conference. 14th Meeting of the IBCN. Bochum, DE.
- 2015. MRI Imaging As A Screening Tool for Prostate Cancer. Conference. 2015 International Uro-Oncological Symposium: Update on the Management of Urologic Malignancies, TW.
- 2015. The Future of Cystectomy is Robotic Cystectomy. Conference. 2015 International Uro-Oncological Symposium: Update on the Management of Urologic Malignancies, TW.
- 2015. Limitations In Bladder Cancer Staging. Conference. 2015 International Uro-Oncological Symposium: Update on the Management of Urologic Malignancies, TW.
- 2015. Initial Results of Robotic Cystectomy With Introcorporeal Ilieal Conduit Urinary Diversion. Conference. Initial Results of Robotic Cystectomy With Introcorporeal Ilieal Conduit Urinary Diversion, GR.
- 2015. Second Line Therapy for BCG Failure: When The Patient Refuses Cystectomy. Conference. Second Line Therapy for BCG Failure: When The Patient Refuses Cystectomy, KW.
- 2015. NMIBC: Rational For Upfront Cystectomy. Conference. NMIBC: Rational For Upfront Cystectomy, KW.
- 2015. Robotic Cystectomy (Male and Female) Technique. Conference. Robotic Cystectomy (Male and Female) Technique, KW.
Formal Peers
- 2022. Innovations in Virtual Care. Invited. Houston, TX, US.
- 2021. Telemedicine in the Oncology Setting: A Panel Discussion. Invited. San Diego, CA, US.
- 2015. Advanced Robotic Surgery Workshop. Invited. Kuwait City, KW.
- 2014. Second Line Therapy for Non Muscle Invasive Bladder Cancer. Invited. Houston, TX, US.
- 2013. Active Surveillance for Prostate Cancer. Invited. Houston, TX, US.
Grant & Contract Support
| Date: | 2016 - 2019 |
| Title: | The UT MD Anderson SPORE in Genitourinary Cancer / Career Development Award: MRI Evaluation and Staging of Bladder Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | P50 CA091846 |
| Date: | 2016 - 2017 |
| Title: | Career Enhancement Program (CEP) of The UT MD Anderson SPORE in Genitourinary Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2014 - 2016 |
| Title: | The UT MD Anderson SPORE in Genitourinary Cancer / Career Development Award: MRI Evaluation and Staging of Bladder Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | NIH CA09184 |
| Date: | 2012 - 2014 |
| Title: | The UT MD Anderson SPORE in Genitourinary Cancer / Career Development Award: MRI Evaluation and Staging of Bladder Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | NIH CA09184 |
| Date: | 2011 - 2012 |
| Title: | MicroRNA Control of Growth Factor Resistance in Bladder Cancer |
| Funding Source: | AUA Foundation (now Urology Care Foundation) |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Lee, S, Jung, SY, Kuś, P, Bondaruk, J, Lee, JG, Jaksik, R, Putluri, N, Dinh, KN, Cogdell, D, Chen, H, Wang, Y, Chen, J, Navai, N, Dinney, CP, Mendelsohn, C, McConkey, DJ, Behringer, RR, Guo, CC, Wei, P, Kimmel, M, Czerniak, BA. Dysregulated mitochondrial energy metabolism drives the progression of mucosal field effects to invasive bladder cancer. Journal of Pathology 267(3):329-346, 2025. e-Pub 2025. PMID: 40996337.
- Carriere, P, Alhalabi, O, Gao, J, Mohamad, O, Campbell, M, Shah, AY, Goswami, S, Bree, KK, Lee, B, Navai, N, Mok, H, Mayo, LL, Guo, CC, Nguyen, Q, McGuire, SE, Park, R, Shah, SJ, Hoffman, K, Frank, SJ, Tang, C, Choi, S, Kamat, A, Hassanzadeh, CJ. Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer. Clinical and Translational Radiation Oncology 49, 2024. e-Pub 2024. PMID: 39403573.
- Carriere P, Alhalabi O, Gao J, Mohamad O, Campbell MT, Shah A, Goswami S, Bree K, Lee B, Navai N, Mok H, Mayo L, Guo C, Nguyen Q, McGuire S, Park R, Shah S, Hoffman K, Frank S, Tang C, Choi S, Kamat A, Hassanzadeh C. Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer. Clin Transl Radiat Oncol 49:100866, 2024. e-Pub 2024. PMID: 39403573.
- Campbell MT, Shah AY, Msaouel P, Tannir NM, Siefker-Radtke AO, Kamat AM, Navai N, Dinney CPN, Rao P, Guo CC, Sheth RA, Venkatesan AM, Tidwell RS, Yadav SS, Gu A, Chen H, Macaluso M, Duan F, Basu S, Jindal S, Sharma P. A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer. Cancer Res Commun 4(9):2444-2453, 2024. e-Pub 2024. PMID: 39207194.
- Contieri, R, Tan, WS, Grajales, V, Hensley, PJ, Martini, A, Bree, KK, Myers, AA, Nogueras Gonzalez, G, Navai, N, Dinney, CP, Guo, CC, Kamat, A. Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy. BJU international 133(6):733-741, 2024. e-Pub 2024. PMID: 38374533.
- Lee, S, Bondaruk, J, Wang, Y, Chen, H, Lee, JG, Majewski, T, Mullen, RD, Cogdell, D, Chen, J, Wang, Z, Yao, H, Kuś, P, Jeong, J, Lee, I, Choi, W, Navai, N, Guo, C, Dinney, CP, Baggerly, KA, Mendelsohn, C, McConkey, D, Behringer, RR, Kimmel, M, Wei, P, Czerniak, BA. Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesis. Cell Reports 43(5), 2024. e-Pub 2024. PMID: 38676926.
- Sood, A, Rudzinski, JK, Labbate, CV, Hensley, PJ, Bree, KK, Guo, CC, Alhalabi, O, Campbell, M, Siefker-Radtke, AO, Navai, N, Dinney, CP, Gao, J, Kamat, A. Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer. Journal of Urology 211(2):241-255, 2024. e-Pub 2024. PMID: 37922370.
- Contieri, R, Grajales, V, Tan, WS, Martini, A, Sood, A, Hensley, PJ, Bree, KK, Lobo, N, Nogueras Gonzalez, G, Guo, CC, Navai, N, Dinney, CP, Kamat, A. Impact of age >70 years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette–Guérin. BJU international 133(1):63-70, 2024. e-Pub 2024. PMID: 37442564.
- Alhalabi, O, Wilson, NR, Xiao, L, Lin, Y, Khandelwal, J, Moussa, MJ, Msaouel, P, Navai, N, Gao, J, Kamat, A, Pilie, PG, Shah, AY, Goswami, S, Matin, S, Kovitz, CA, Holla, V, Guo, C, Czerniak, BA, Logothetis, CJ, Corn, P, Dinney, CP, Campbell, M, Hansel, DE, Tannir, NM, Siefker-Radtke, AO. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. European Urology Oncology 6(6):611-620, 2023. e-Pub 2023. PMID: 37833193.
- Contieri, R, Hensley, PJ, Tan, WS, Grajales, V, Bree, KK, Nogueras Gonzalez, G, Lee, B, Navai, N, Dinney, CP, Kamat, A. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. European Urology Oncology 6(6):590-596, 2023. e-Pub 2023. PMID: 37558542.
- Tan, WS, McElree, IM, Davaro, F, Steinberg, RL, Bree, KK, Navai, N, Dinney, CP, O'Donnell, M, Li, R, Kamat, A, Packiam, V. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. European Urology Oncology 6(5):531-534, 2023. e-Pub 2023. PMID: 37468392.
- Tan, WS, Grajales, V, Contieri, R, Hensley, PJ, Bree, KK, Msaouel, P, Guo, CC, Nogueras Gonzalez, G, Navai, N, Dinney, CP, Kamat, A. Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer. European Urology Open Science 53:16-22, 2023. e-Pub 2023. PMID: 37441349.
- Wang, XS, Bree, KK, Navai, N, Jomaa, M, Shen, SE, Letona, E, Cleeland, C, Shi, Q, Gottumukkala, V. Utility of Patient-Reported Symptom and Functional Outcomes to Indicate Recovery after First 90 Days of Radical Cystectomy. Cancers 15(11), 2023. e-Pub 2023. PMID: 37297013.
- Hensley, PJ, Duan, Z, Bree, KK, Sood, A, Zhao, H, Lobo, N, Contieri, R, Campbell, M, Guo, CC, Navai, N, Williams, SB, Dinney, CP, Kamat, A. Competing mortality risk from second primary malignancy in bladder cancer patients following radical cystectomy. Urologic Oncology: Seminars and Original Investigations 41(2):108.e11-108.e17, 2023. e-Pub 2023. PMID: 36404232.
- Bree, KK, Kokorovic, A, Westerman, ME, Hensley, PJ, Brooks, NA, Qiao, W, Shen, Y, Kamat, A, Dinney, CP, Navai, N. Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy is Prognostic but Not Therapeutic. Journal of Urology 209(1):140-149, 2023. e-Pub 2023. PMID: 36250944.
- Westerman, ME, Bree, KK, Msaouel, P, Kukreja, JB, Mantaring, C, Rukundo, I, Gonzalez, MG, Gregg, JR, Casteel, KN, Matin, S, Lafleur, AD, Best, RN, Crump, LD, Cunningham, JM, Saucedo, MA, Valle, DD, Varghese, R, Adibi, M, Chapin, BF, Chery, LJ, Davis, JW, Dinney, CP, Graber, WJ, Kamat, A, Karam, JA, Navai, N, Papadopoulos, JN, Pettaway, CA, Pisters, LL, Smith III, T, Ward, JF, Westney, OL, Wood, CG. Apixaban vs Enoxaparin for Post-Surgical Extended-Duration Venous Thromboembolic Event Prophylaxis. Journal of Urology 208(4):886-895, 2022. e-Pub 2022. PMID: 36082549.
- Labbate, CV, Hensley, PJ, Miest, T, Qiao, W, Adibi, M, Shah, AY, Chery, LJ, Papadopoulos, JN, Siefker-Radtke, AO, Gao, J, Guo, CC, Czerniak, BA, Navai, N, Kamat, A, Dinney, CP, Campbell, M, Matin, S. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations 40(10):454.e17-454.e23, 2022. e-Pub 2022. PMID: 35961847.
- Lobo, N, Hensley, PJ, Bree, KK, Nogueras Gonzalez, G, Navai, N, Dinney, CP, Kamat, A. Should patients with non-muscle-invasive bladder cancer discontinue fibrin clot inhibitors during bacille Calmette–Guérin?. BJU international 130(4):463-469, 2022. e-Pub 2022. PMID: 34854189.
- Lobo, N, Bree, KK, Hensley, PJ, Nogueras Gonzalez, G, Abraham, P, Navai, N, Dinney, CP, Kamat, A. Reduced-dose bacillus Calmette-Guérin (BCG) in an era of BCG shortage. BJU international 130(3):323-330, 2022. e-Pub 2022. PMID: 34847263.
- Jomaa, M, Navai, N, Bree, KK, Williams, LA, Cleeland, C, Shen, SE, Wang, XS. Validation and Application of MD Anderson Symptom Inventory Module for Patients with Bladder Cancer in the Perioperative Setting. Cancers 14(16), 2022. e-Pub 2022. PMID: 36010890.
- Bree, KK, Hensley, PJ, Lobo, N, Brooks, NA, Nogueras Gonzalez, G, Guo, CC, Navai, N, Barton Grossman, H, Dinney, CP, Kamat, A. All High-Grade Ta Tumors Should Be Classified as High Risk. Journal of Urology 208(2):284-291, 2022. e-Pub 2022. PMID: 35770498.
- Bondaruk, J, Jaksik, R, Wang, Z, Cogdell, D, Lee, S, Chen, Y, Dinh, KN, Majewski, T, Zhang, L, Cao, S, Tian, F, Yao, H, Kuś, P, Chen, H, Weinstein, JN, Navai, N, Dinney, CP, Gao, J, Theodorescu, D, Logothetis, CJ, Guo, CC, Wang, W, McConkey, DJ, Wei, P, Kimmel, M, Czerniak, BA. The origin of bladder cancer from mucosal field effects. iScience 25(7), 2022. e-Pub 2022. PMID: 35747385.
- Hensley, PJ, Bree, KK, Brooks, NA, Matulay, JT, Li, R, Nogueras Gonzalez, G, Nagaraju, S, Navai, N, Barton Grossman, H, Dinney, CP, Kamat, A. Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes. European Urology Oncology 5(3):347-356, 2022. e-Pub 2022. PMID: 33935020.
- Adibi, M, McCormick, B, Economides, MP, Petros, FG, Xiao, L, Guo, CC, Shah, AY, Kamat, A, Dinney, CP, Navai, N, Gao, J, Siefker-Radtke, AO, Matin, S, Campbell, M. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clinical Genitourinary Cancer 20(2):176-182, 2022. e-Pub 2022. PMID: 35039231.
- Khanna, A, Miest, T, Sharma, V, Campbell, R, Hensley, PJ, Thapa, P, Zganjar, A, Tollefson, MK, Thompson, RH, Frank, I, Karnes, RJ, Murthy, PB, Haber, GP, Navai, N, Kamat, A, Dinney, CP, Lee, B, Boorjian, SA. Role of Lymphadenectomy during Radical Cystectomy for Nonmuscle-Invasive Bladder Cancer. Journal of Urology 207(3):551-558, 2022. e-Pub 2022. PMID: 34694143.
- Lobo, N, Hensley, PJ, Bree, KK, Nogueras Gonzalez, G, Navai, N, Dinney, CP, Sylvester, R, Kamat, A. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin. European Urology Oncology 5(1):84-91, 2022. e-Pub 2022. PMID: 34920986.
- Sood, A, Keeley, J, Palma-Zamora, I, Novara, G, Elshaikh, M, Jeong, W, Hensley, PJ, Navai, N, Peabody, JO, Trinh, QD, Rogers, CG, Menon, M, Abdollah, F. High-intensity local treatment of clinical node-positive urothelial carcinoma of the bladder alongside systemic chemotherapy improves overall survival. Urologic Oncology: Seminars and Original Investigations 40(2):62.e1-62.e11, 2022. e-Pub 2022. PMID: 34348860.
- Alhalabi, O, Campbell, M, Xiao, L, Adriazola, AC, Wilson, NR, Siefker-Radtke, AO, Corn, P, Zurita-Saavedra, A, Jonasch, E, Gao, J, Adibi, M, Kamat, A, Navai, N, Pisters, LL, Dinney, CP, Matin, S, Shah, AY. Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI Compass 3(1):37-44, 2022. e-Pub 2022. PMID: 35475152.
- Westerman, ME, Bree, KK, Kokorovic, A, Frank, J, Wang, XS, Kamat, A, Dinney, CP, Navai, N. What Women Want. Urology 157:181-187, 2021. e-Pub 2021. PMID: 34186127.
- Bree, KK, Hensley, PJ, Brooks, NA, Matulay, JT, Nogueras Gonzalez, G, Navai, N, Dinney, CP, Kamat, A. Impact of sex on response to BCG in non-muscle invasive bladder cancer patients. World journal of urology 39(11):4143-4149, 2021. e-Pub 2021. PMID: 34117914.
- Hensley, PJ, Bree, KK, Campbell, M, Alhalabi, O, Kokorovic, A, Miest, T, Nogueras Gonzalez, G, Gao, J, Siefker-Radtke, AO, Guo, CC, Navai, N, Dinney, CP, Kamat, A. Progression of Disease after Bacillus Calmette-Guérin Therapy. Journal of Urology 206(5):1258-1266, 2021. e-Pub 2021. PMID: 34184926.
- Hensley, PJ, Bree, KK, Brooks, NA, Matulay, JT, Li, R, Nogueras Gonzalez, G, Navai, N, Barton Grossman, H, Dinney, CP, Kamat, A. Time interval from transurethral resection of bladder tumour to bacille Calmette–Guérin induction does not impact therapeutic response. BJU international 128(5):634-641, 2021. e-Pub 2021. PMID: 33783950.
- Hensley, PJ, Bree, KK, Campbell, M, Alhalabi, O, Kokorovic, A, Miest, T, Nogueras Gonzalez, G, Gao, J, Siefker-Radtke, AO, Guo, CC, Navai, N, Dinney, CP, Kamat, A. Reply by Authors. The Journal of Urology 206(5):1267, 2021. e-Pub 2021. PMID: 34372685.
- Bree, KK, Hensley, PJ, Brooks, NA, Matulay, JT, Li, R, Nogueras Gonzalez, G, Navai, N, Barton Grossman, H, Matin, S, Dinney, CP, Kamat, A. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer. BJU international 128(5):568-574, 2021. e-Pub 2021. PMID: 33484074.
- Bree, KK, Hensley, PJ, Westerman, ME, Kokorovic, A, Nogueras Gonzalez, G, Dinney, CP, Kamat, A, Navai, N. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer. Journal of Urology 206(3):577-585, 2021. e-Pub 2021. PMID: 33872050.
- Kukreja, JB, Li, R, Narayan, VM, Lim, A, Seif, MA, Wang, X, Kamat, A, Dinney, CP, Navai, N. Oncologic Equipoise between Robotic and Open Radical Cystectomy. Journal of Endourology 35(8):1168-1176, 2021. e-Pub 2021. PMID: 33619985.
- Brooks, NA, Kokorovic, A, Xiao, L, Matulay, JT, Li, R, Ranasinghe, WK, Nagaraju, S, Shen, Y, Gao, J, Navai, N, Dinney, CP, Barton Grossman, H, Kamat, A. The obesity paradox. BJU international 128(1):65-71, 2021. e-Pub 2021. PMID: 33210440.
- Matulay, JT, Li, R, Hensley, PJ, Brooks, NA, Narayan, VM, Barton Grossman, H, Navai, N, Dinney, CP, Kamat, A. Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin. Journal of Urology 205(6):1612-1619, 2021. e-Pub 2021. PMID: 33502236.
- Kukreja, JB, Seif, MA, Mery, MW, Incalcaterra, JR, Kamat, A, Dinney, CP, Shah, JB, Feeley, TW, Navai, N. Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers. Urologic Oncology: Seminars and Original Investigations 39(4):237.e1-237.e5, 2021. e-Pub 2021. PMID: 33308972.
- Millward, NZ, Wang, L, Maity, T, Li, L, Millward, S, Karam, JA, Wood, CG, Navai, N. Prolyl hydroxylase 3 knockdown accelerates VHL-mutant kidney cancer growth in vivo. International journal of molecular sciences 22(6):1-16, 2021. e-Pub 2021. PMID: 33799686.
- Kokorovic, A, Westerman, ME, Krause, KJ, Hernandez, M, Brooks, NA, Dinney, CP, Kamat, A, Navai, N. Revisiting an Old Conundrum. Bladder Cancer 7(2):243-252, 2021. e-Pub 2021. PMID: 34195319.
- Gao, J, Navai, N, Alhalabi, O, Siefker-Radtke, AO, Campbell, M, Tidwell, R, Guo, CC, Kamat, A, Matin, S, Araujo, JC, Shah, AY, Msaouel, P, Corn, P, Wang, J, Papadopoulos, JN, Yadav, SS, Blando, J, Duan, F, Basu, S, Liu, W, Shen, Y, Zhang, Y, Macaluso, M, Wang, Y, Chen, J, Zhang, J, Futreal, A, Dinney, CP, Allison, JP, Goswami, S, Sharma, P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nature medicine 26(12):1845-1851, 2020. e-Pub 2020. PMID: 33046869.
- Westerman, ME, Kokorovic, A, Wang, XS, Lim, A, Garcia-Gonzalez, A, Seif, MA, Wang, R, Kamat, A, Dinney, CP, Navai, N. Radical Cystectomy and Perioperative Sexual Function. Journal of Sexual Medicine 17(10):1995-2004, 2020. e-Pub 2020. PMID: 32713807.
- Mokkapati, S, Porten, S, Narayan, VM, Lim, A, Jayaratna, IS, Roth, B, Roth, B, Cheng, T, Navai, N, Wszolek, MF, Melquist, J, Manyam, GC, Choi, W, Broom, BM, Pretzsch, SM, Czerniak, BA, McConkey, DJ, Dinney, CP. TCF21 promotes luminal-like differentiation and suppresses metastasis in bladder cancer. Molecular Cancer Research 18(6):811-821, 2020. e-Pub 2020. PMID: 32122956.
- Mokkapati, S, Porten, S, Narayan, VM, Lim, A, Jayaratna, IS, Roth, B, Roth, B, Cheng, T, Navai, N, Wszolek, MF, Melquist, J, Manyam, GC, Choi, W, Broom, BM, Pretzsch, SM, Czerniak, BA, McConkey, DJ, Dinney, CP. TCF21 promotes luminal-like differentiation and suppresses metastasis in bladder cancer. Molecular Cancer Research 18(6):811-821, 2020. e-Pub 2020. PMID: 32122956.
- Narayan, VM, Seif, MA, Lim, A, Li, R, Matulay, JT, Kukreja, JB, Qiao, W, Hwang, H, Shah, JB, Pisters, LL, Kamat, A, Dinney, CP, Navai, N. Radical cystectomy in women. Urologic Oncology: Seminars and Original Investigations 38(4):247-254, 2020. e-Pub 2020. PMID: 31953001.
- Williams III, WH, Cata, JP, Lasala, J, Navai, N, Feng, L, Gottumukkala, V. Effect of reversal of deep neuromuscular block with sugammadex or moderate block by neostigmine on shoulder pain in elderly patients undergoing robotic prostatectomy. British journal of anaesthesia 124(2):164-172, 2020. e-Pub 2020. PMID: 31780139.
- Tang, C, Hoffman, K, Allen, P, Gabel, M, Schreiber, D, Choi, S, Chapin, BF, Nguyen, Q, Davis, JW, Corn, P, Logothetis, CJ, Ward, JF, Frank, SJ, Navai, N, McGuire, SE, Anscher, MS, Pisters, LL, Pettaway, CA, Kumar, R, Linson, PW, Tripuraneni, P, Tomaszewski, JJ, Patel, AB, Augspurger, ME, Kuban, DA. Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer 126(3):506-514, 2020. e-Pub 2020. PMID: 31742674.
- Kukreja, JB, Metcalfe, MJ, Qiao, W, Kamat, A, Dinney, CP, Navai, N. Cost-Effectiveness of Robot-assisted Radical Cystectomy Using a Propensity-matched Cohort. European Urology Focus 6(1):88-94, 2020. e-Pub 2020. PMID: 30033071.
- Li, R, Kukreja, JB, Seif, MA, Petros, FG, Campbell, M, Nguyen, JV, Nogueras Gonzalez, G, Kamat, A, Pisters, LL, Dinney, CP, Navai, N. The role of metastatic burden in cytoreductive/consolidative radical cystectomy. World journal of urology 37(12):2691-2698, 2019. e-Pub 2019. PMID: 30864005.
- Li, R, Metcalfe, MJ, Tabayoyong, W, Guo, CC, Nogueras Gonzalez, G, Navai, N, Barton Grossman, H, Dinney, CP, Kamat, A. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin. European Urology Oncology 2(3):286-293, 2019. e-Pub 2019. PMID: 31200843.
- Marcus, R, Lillemoe, HA, Rice, DC, Mena, GE, Bednarski, BK, Speer, BB, Ramirez, PT, Lasala, J, Navai, N, Williams III, WH, Kim, BJ, Voss, RK, Gottumukkala, V, Aloia, TA. Determining the Safety and Efficacy of Enhanced Recovery Protocols in Major Oncologic Surgery. Annals of surgical oncology 26(3):782-790, 2019. e-Pub 2019. PMID: 30627879.
- Li, R, Tabayoyong, W, Guo, CC, Nogueras Gonzalez, G, Navai, N, Barton Grossman, H, Dinney, CP, Kamat, A. Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease [Figure presented]. European urology 75(1):8-10, 2019. e-Pub 2019. PMID: 30301695.
- Balasubramanian, A, Metcalfe, MJ, Wagenheim, G, Xiao, L, Papadopoulos, JN, Navai, N, Davis, JW, Karam, JA, Kamat, A, Wood, CG, Dinney, CP, Matin, S. Salvage topical therapy for upper tract urothelial carcinoma. World journal of urology 36(12):2027-2034, 2018. e-Pub 2018. PMID: 29804202.
- Kukreja, JB, Porten, S, Golla, V, Ho, PL, Noguera-Gonzalez, G, Navai, N, Kamat, A, Dinney, CP, Shah, JB. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. European Urology Focus 4(5):720-724, 2018. e-Pub 2018. PMID: 28753837.
- Mmeje, CO, Benson, CR, Nogueras Gonzalez, G, Jayaratna, IS, Gao, J, Siefker-Radtke, AO, Kamat, A, Dinney, CP, Navai, N, Shah, JB. Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy. BJU international 122(1):89-98, 2018. e-Pub 2018. PMID: 29569824.
- Kukreja, JB, Shi, Q, Chang, CM, Seif, MA, Sterling, BM, Chen, TY, Creel, KM, Kamat, A, Dinney, CP, Navai, N, Shah, JB, Wang, XS. Patient-Reported Outcomes Are Associated With Enhanced Recovery Status in Patients With Bladder Cancer Undergoing Radical Cystectomy. Surgical Innovation 25(3):242-250, 2018. e-Pub 2018. PMID: 29557251.
- Chapin, BF, Nguyen, JN, Achim, M, Navai, N, Williams, SB, Prokhorova, IN, Wang, X, Li Ning Tapia, E, Davis, JW, Troncoso, P. Positive margin length and highest Gleason grade of tumor at the margin predict for biochemical recurrence after radical prostatectomy in patients with organ-confined prostate cancer. Prostate Cancer and Prostatic Diseases 21(2):221-227, 2018. e-Pub 2018. PMID: 29230008.
- Blanchard, P, Davis, JW, Frank, SJ, Kim, J, Pettaway, CA, Pugh, T, Pisters, LL, Ward, JF, Choi, S, Chapin, BF, Hoffman, K, Navai, N, Achim, M, McGuire, SE, Matin, S, Nguyen, Q, Mahmood, U, Graber, WJ, Chen, HC, Wang, X, Kuban, DA. Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer. BJU international 121(4):540-548, 2018. e-Pub 2018. PMID: 28941030.
- Li, R, Metcalfe, MJ, Ferguson, JE, Mokkapati, S, Nogueras Gonzalez, G, Dinney, CP, Navai, N, McConkey, DJ, Sahai, SK, Kamat, A. Effects of thiazolidinedione in patients with active bladder cancer. BJU international 121(2):244-251, 2018. e-Pub 2018. PMID: 28872778.
- Li R, Metcalfe M, Kukreja J, Navai N. Role of Radical Cystectomy in Non-Organ Confined Bladder Cancer: A Systematic Review. Bladder Cancer 4(1):31-40, 2018. e-Pub 2018. PMID: 29430505.
- Basourakos, SP, Davis, JW, Chapin, BF, Ward, JF, Pettaway, CA, Pisters, LL, Navai, N, Achim, M, Wang, X, Chen, HC, Choi, S, Kuban, DA, Troncoso, P, Hanash, S, Thompson, T, Kim, J. Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU international 121(1):69-76, 2018. e-Pub 2018. PMID: 28710901.
- Biebighauser, KC, Gao, J, Rao, P, Landon, G, Pagliaro, LC, Dinney, CP, Karam, JA, Navai, N. Non-seminomatous germ cell tumor with bone metastasis only at diagnosis. Asian Journal of Urology 4(2):124-127, 2017. e-Pub 2017. PMID: 29264217.
- Roth, B, Jayaratna, IS, Sundi, D, Cheng, T, Melquist, J, Choi, W, Porten, S, Nitti, G, Navai, N, Wszolek, MF, Guo, CC, Czerniak, BA, McConkey, DJ, Dinney, CP. Employing an orthotopic model to study the role of epithelialmesenchymal transition in bladder cancer metastasis. Oncotarget 8(21):34205-34222, 2017. e-Pub 2017. PMID: 27494900.
- Navai, N, Benedict, WF, Zhang, G, Abraham, A, Ainslie, N, Shah, JB, Barton Grossman, H, Kamat, A, Dinney, CP. Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette–Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer. Annals of surgical oncology 23(12):4110-4114, 2016. e-Pub 2016. PMID: 27387678.
- Ho, PL, Willis, DL, Patil, J, Xiao, L, Williams, SB, Melquist, J, Tart, K, Parikh, S, Shah, JB, Delacroix, SE, Navai, N, Siefker-Radtke, AO, Dinney, CP, Pisters, LL, Kamat, A. Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy. Urologic Oncology: Seminars and Original Investigations 34(2):59.e1-59.e8, 2016. e-Pub 2016. PMID: 26421586.
- Culp, SH, Dickstein, RJ, Barton Grossman, H, Pretzsch, SM, Porten, S, Daneshmand, S, Cai, J, Groshen, S, Siefker-Radtke, AO, Millikan, RE, Czerniak, BA, Navai, N, Wszolek, MF, Kamat, A, Dinney, CP. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. Journal of Urology 191(1):40-47, 2014. e-Pub 2014. PMID: 23911605.
- Solomon, DA, Kim, JS, Bondaruk, J, Shariat, SF, Wang, ZF, Elkahloun, AG, Ozawa, T, Gerard, J, Zhuang, D, Zhang, S, Navai, N, Siefker-Radtke, AO, Phillips, J, Robinson, B, Rubin, MA, Volkmer, BG, Hautmann, R, Küfer, R, Hogendoorn, PC, Netto, G, Theodorescu, D, James, CD, Czerniak, BA, Miettinen, M, Waldman, T. Frequent truncating mutations of STAG2 in bladder cancer. Nature Genetics 45(12):1428-1430, 2013. e-Pub 2013. PMID: 24121789.
- Dinney, CP, Fisher, MB, Navai, N, O'Donnell, M, Cutler, D, Abraham, A, Young, S, Hutchins, B, Caceres, M, Kishnani, N, Sode, G, Cullen, C, Zhang, G, Barton Grossman, H, Kamat, A, Gonzales, M, Kincaid, M, Ainslie, N, Maneval, DC, Wszolek, MF, Benedict, WF. Phase i trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in syn3 for bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer. Journal of Urology 190(3):850-856, 2013. e-Pub 2013. PMID: 23507396.
- Tran, MN, Choi, W, Wszolek, MF, Navai, N, Lee, IC, Nitti, G, Wen, S, Flores, ER, Siefker-Radtke, AO, Czerniak, BA, Dinney, CP, Barton, M, McConkey, DJ. The p63 protein isoform ΔNp63α inhibits epithelial-mesenchymal transition in human bladder cancer cells. Journal of Biological Chemistry 288(5):3275-3288, 2013. e-Pub 2013. PMID: 23239884.
- Rebuck, DA, Zhao, LC, Helfand, BT, Casey, JT, Navai, N, Perry, KT, Nadler, RB. Simple modifications in operating room processes to reduce the times and costs associated with robot-assisted laparoscopic radical prostatectomy. Journal of Endourology 25(6):955-960, 2011. e-Pub 2011. PMID: 21457071.
- Alphs, HH, Navai, N, Köhler, TS, McVary, KT. Preoperative clinical and diagnostic characteristics of patients who require delayed ipp after primary peyronies repair. Journal of Sexual Medicine 7(3):1262-1268, 2010. e-Pub 2010. PMID: 20059657.
- Nadler, RB, Casey, JT, Zhao, LC, Navai, N, Smith, ZL, Zhumkhawala, A, Macejko, AM. Is the transition from open to robotic prostatectomy fair to your patients? A single-surgeon comparison with 2-year follow-up. Journal of Robotic Surgery 3(4):201-207, 2010. e-Pub 2010. PMID: 27628630.
- Meeks, JJ, Zhao, LC, Navai, N, Perry, KT, Nadler, RB, Smith, ND. Risk Factors and Management of Urine Leaks After Partial Nephrectomy. Journal of Urology 180(6):2375-2378, 2008. e-Pub 2008. PMID: 18930268.
- Casey, JT, Erickson, BA, Navai, N, Zhao, LC, Meeks, JJ, Gonzalez, CM. Urethral Reconstruction in Patients With Neurogenic Bladder Dysfunction. Journal of Urology 180(1):197-200, 2008. e-Pub 2008. PMID: 18499188.
- Erickson, BA, Navai, N, Patil, M, Chang, A, Gonzalez, CM. A Prospective, Randomized Trial Evaluating the Use of Hydrogel Coated Latex Versus All Silicone Urethral Catheters After Urethral Reconstructive Surgery. Journal of Urology 179(1):203-206, 2008. e-Pub 2008. PMID: 18001794.
- Navai, N, Erickson, BA, Zhao, LC, Okotie, OT, Gonzalez, CM. Complications following urethral reconstructive surgery. International Braz J Urol 34(5):594-601, 2008. e-Pub 2008. PMID: 18986563.
- Navai, N, Yap, RL, Gupta, R, Fraserand, TG, Gonzalez, CM. Inflammatory pseudotumor of the testis. International Journal of Urology 12(4):424-426, 2005. e-Pub 2005. PMID: 15948738.
- Saporita, AJ, Zhang, Q, Navai, N, Dincer, Z, Hahn, J, Cai, X, Wang, Z. Identification and Characterization of a Ligand-regulated Nuclear Export Signal in Androgen Receptor. Journal of Biological Chemistry 278(43):41998-42005, 2003. e-Pub 2003. PMID: 12923188.
- Saporita, AJ, Zhang, Q, Navai, N, Dincer, Z, Hahn, J, Cai, X, Wang, Z. Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor. European Urology, Supplements 2(6):73, 2003. e-Pub 2003.
- Mmeje, CO, Guo, CC, Shah, JB, Navai, N, Barton Grossman, H, Dinney, CP, Kamat, A. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy. European urology 70(5):778-785. PMID: 26922408.
- Metcalfe, MJ, Ferguson, JE, Li, R, Xiao, L, Guo, CC, Czerniak, BA, Siefker-Radtke, AO, Pretzsch, SM, Navai, N, McConkey, DJ, Kamat, A, Campbell, M, Dinney, CP. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. European Urology Focus 3(6):577-583. PMID: 28753816.
Review Articles
- Gupta S, Hensley PJ, Li R, Choudhury A, Daneshmand S, Faltas BM, Flaig TW, Grass GD, Grivas P, Hansel DE, Hassanzadeh C, Kassouf W, Kukreja J, Mendoza-Valdes A, Moschini M, Mouw KW, Navai N, Necchi A, Rosenberg JE, Ross JS, Siefker-Radtke AO, Taylor J, Willliams SB, Zlotta AR, Buckley R, Kamat AM. Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group. Eur Urol, 2025. e-Pub 2025. PMID: 40268594.
- Cohen, AB, Stump, L, Krumholz, HM, Cartiera, M, Jain, S, Scott Sussman, L, Hsiao, A, Lindop, W, Ying, AK, Kaul, RL, Balcezak, TJ, Tereffe, W, Comerford, M, Jacoby, D, Navai, N. Aligning mission to digital health strategy in academic medical centers. npj Digital Medicine 5(1), 2022. e-Pub 2022. PMID: 35654885.
- Lim, A, Westerman, ME, Korokovic, A, Matulay, JT, Narayan, VM, Navai, N. Efficacy of Surgery on the Primary Tumour in Patients with Metastatic Bladder Cancer. Bladder Cancer 8(2):193-209, 2022. e-Pub 2022. PMID: 38993364.
- Metcalfe, MJ, Wagenheim, G, Xiao, L, Papadopoulos, JN, Navai, N, Davis, JW, Karam, JA, Kamat, A, Wood, CG, Dinney, CP, Matin, S. Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma. Journal of Endourology 31(9):946-953, 2017. e-Pub 2017. PMID: 28731777.
- Jayaratna, IS, Navai, N, Dinney, CP. Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer. Translational Andrology and Urology 4(3):273-282, 2015. e-Pub 2015. PMID: 26816830.
- Navai, N, Wood, CG. Environmental and modifiable risk factors in renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 30(2):220-224, 2012. e-Pub 2012. PMID: 22385993.
Other Articles
- Tan, WS, Grajales, V, Bree, KK, Li, R, Nogueras Gonzalez, G, Navai, N, Dinney, CP, Kamat, A Bacillus Calmette–Guérin (BCG) unresponsive non-muscle-invasive bladder cancer. BJU international 132(4):384-386, 2023. PMID: 37246493.
- Bondaruk, J, Jaksik, R, Wang, Z, Cogdell, D, Lee, S, Chen, Y, Dinh, KN, Majewski, T, Zhang, L, Cao, S, Tian, F, Yao, H, Kuś, P, Chen, H, Weinstein, JN, Navai, N, Dinney, CP, Gao, J, Theodorescu, D, Logothetis, CJ, Guo, CC, Wang, W, McConkey, DJ, Wei, P, Kimmel, M, Czerniak, BA Erratum. iScience 25(7), 2022. PMID: 35811851.
- Matulay, JT, Li, R, Hensley, PJ, Brooks, NA, Narayan, VM, Barton Grossman, H, Navai, N, Dinney, CP, Kamat, A Reply by Authors. Journal of Urology 205(6):1620-1621, 2021. PMID: 33734859.
- Pessoa, R, Navai, N, Kukreja, JB EDITORIAL COMMENT. Urology 135:64-65, 2020. PMID: 31895682.
- Navai, N, Matin, S Re. European urology 67(1):173-174, 2015. PMID: 25528394.
- Navai, N, Matin, S In vivo microwave-induced porcine kidney thermoablation. Journal of Endourology 25(6):908-909, 2011.
- Navai, N, Matin, S Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles - Commentary. Journal of Endourology 25(6):909-910, 2011.
- Alphs, HH, Navai, N, Köhler, TS, McVary, KT Preoperative clinical and diagnostic characteristics of patients who require delayed ipp after primary Peyronie's repair. Journal of Urology 184(4):1392-1393, 2010.
Editorials
- Lim, A, Narayan, VM, Navai, N. The Role of Surgery in Initially Metastatic Urothelial Carcinoma. European Urology Oncology 3(1):102-103, 2020. PMID: 31501083.
- Navai, N, Dinney, CP. Oncologic Equivalence between Laparoscopic/Robotic and Open Radical Cystectomy. Journal of Urology 195(6):1646-1647, 2016. PMID: 26994308.
- Navai, N, Ramos, P, Zhao, LC, Meeks, JJ, Nadler, RB, Smith, ND. Why Not Partial Nephrectomy?. Urology 72(2):243-246, 2008. PMID: 18584853.
Abstracts
- Sood A, Lim A. Pathologic Downstaging Rate and Predictive Biomarker Exploration in Patients with Biopsy-Proven Clinically Node Positive Bladder Cancer Undergoing Chemotherapy Followed by Radical Cystectomy, 2023. e-Pub 2023.
- N Dinney APMSMNNAMKDJMCP. GENERATION AND VALIDATION OF A PREDICTIVE URINE-MICRORNA SIGNATURE FOR INTRAVESICAL BCG THERAPY, 2022. e-Pub 2022.
- M Kamat ASJKRCVLPJHKKBCCGOAMTCAOSNNCPDJGA. LONG-TERM ONCOLOGICAL OUTCOMES IN PATIENTS DIAGNOSED WITH NON-METASTATIC PLASMACYTOID VARIANT OF BLADDER CANCER: A 20-YEAR UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER EXPERIENCE, 2022. e-Pub 2022.
- Hensley P, Lobo N, Bree K, Sood A, Navai N, Dinney C, Kamat AA. TIMING OF RADICAL CYSTECTOMY FOR BCG FAILURE. The Journal of Urology, 2022. e-Pub 2022.
- Bree KK, Hensley PJ, Brooks NA, Nogueras-Gonzalez GM, Navai N, Grossman HB, Dinney CP, Kamat AM. All HG NMIBC is high risk: BCG response in HG Ta lesions. Eur Urol 79,(1S, Supplement):S990-S991. e-Pub 2021.
- Hensley, PJ, Miest, T, Adibi, M, Campbell, M, Shah, A, Cherry, L, Papadopoulos, J, Siefker-Radtke, A, Gao, J, Guo, C, Czerniak, B, Navai N, Kamat, A, Dinney, C, Matin, S. GFR fluctuation induced by neoadjuvant chemotherapy correlates with pathologic stage of upper tract urothelial carcinoma. Eur Uro 79(S1, Supplement):S1090-S1091. e-Pub 2021.
- Alhalabi O, Wilson N, Navai N, Campbell MT, Shah AY, Gao J, Corn PG, Aparicio A, Czerniak B, Guo C, Logothetis C, Tannir NM, Choi S, Siefker-Radtke AO. Survival outcomes in patients receiving immune checkpoint inhibitor (ICI) for metastatic small cell urothelial cancer (SCUC). Journal of Clinical Oncology 39:4543-4543, 2021. e-Pub 2021.
- Mmeje C, Benson C, Nogueras-Gonzalez G, Jayarantna I, Navai N, Gao J, Siefker-Radtke A, Kamat A, Dinney C, Shah J. Determining The Optimal Timing For Radical Cystectomy After Neoadjuvant Chemotherapy. The Journal of Urology 193(4S, Supplement):e808, 2015. e-Pub 2015.
- Wood EL, Krukreja JEB, Porten S, Qiao W, Ezeagu R, Navai N, Kamat A, Dinney C, Shah JB. Measuring Success After Radical Cystectomy: Feasibility Of A Novel Composite ("Poor Recovery") To Quantify Outcomes After Surgery. The Journal of Urology 193(4S, Supplement):e298, 2015. e-Pub 2015.
- Mmeje CO, Slade AD, Slack RS, Navai N, Kamat AM, Dinney CP, Shah JB. The Utility of Neutrophil-To-Lymphocyte Ratio In Determining Survival Outcomes In Patients Treated With Neoadjuvant Chemotherapy and Radical Cystectomy For High-Risk Bladder Cancer, 2015. e-Pub 2015.
- Golla V, Ho L, Willis DL, Noguera-Gonzalez G, Navai N, Kamat A, Dinney CPN, Shah JB. Absence of Tumor on Repeat TURBT Does Not Predict Final Pathologic T0 Stage In Muscle Invasive Bladder Cancer Treated With Radical Cystectomy. The Journal of Urology 191(4S, Supplement):e501, 2014. e-Pub 2014.
- Culp S, Dickstein R, Pretzsch S, Navai N, Wszolek M, Siefker-Radtke A, Kamat A, Dinney C. Refining Patient Selection For Neoadjuvant Chemotherapy Prior To Radical Cystectomy. The Journal of Urology 187(4S, Supplement):e770, 2012. e-Pub 2012.
- Navai N, Wszolek M, McConkey D, Adam L, Dinney C. Microrna 200C Expression Predicts Overall Survival After Radical Cystectomy. The Journal of Urology 187(4S, Supplement):e434, 2012. e-Pub 2012.
- Navai N, Shikanov S, Pisters L, Eggener S. Decreasing utilization of RPLND for clinical stage I non-seminomatous germ cell tumors. Journal of Urology 187(4S):E305, 2012. e-Pub 2012.
- Navai N, Williams MB, Wen SJ, Siefker-Radtke AO, McConkey DJ, Dinney CPN, Adam L. Relationship between high microRNA-200C expression and the risk of death from disease in muscle-invasive urothelial carcinoma of the bladder. Journal of Clinical Oncology 30(5_suppl):279, 2012. e-Pub 2012.
Book Chapters
- Narayan, VM, Navai, N. Robot-assisted radical cystectomy, 1159-1164, 2021.
- Navai N, Dinney CPN. Surgical Management of Bladder Cancer: Transurethral, Open, and Robotic. In: Campbell-Walsh-Wein Urology. 12th. Elsevier, 3133-3159, 2021.
- Navai N, Dinney CPN. Partial Cystectomy. In: Hinman's Atlas of Urologic Surgery. Elsevier, 349-354, 2021.
- Navai N, Dinney CPN. Transurethral and open surgery for bladder cancer. In: Campbell-Walsh Urology. 11th. Elsevier, 2242-2253, 2016.
Letters to the Editor
- Myers, AA, Tan, WS, Grajales, V, Hwang, H, Bree, KK, Navai, N, Lee, B, Dinney, CP, Kamat, A. Challenging the Paradigm of “BCG-unresponsive” Bladder Cancer. European urology 86: 366-368, 2024.
- Bree, KK, Navai, N. Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply. Journal of Urology 210: 839, 2023.
- Bree K, Navai N. Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply. J Urol 210: 839-840, 2023.
- Bree, KK, Kokorovic, A, Westerman, ME, Hensley, PJ, Brooks, NA, Qiao, W, Shen, Y, Kamat, A, Dinney, CP, Navai, N. Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply. Journal of Urology 210: 254-255, 2023.
- Bree, KK, Hensley, PJ, Lobo, N, Brooks, NA, Nogueras Gonzalez, G, Guo, CC, Navai, N, Barton Grossman, H, Dinney, CP, Kamat, A. Reply by Authors. Journal of Urology 208: 290-291, 2022.
- Bree, KK, Navai, N. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer. Journal of Urology 207: 477, 2022.
Patient Reviews
CV information above last modified February 09, 2026